About
First-in-class FDA De Novo-cleared digital therapeutic for amblyopia (Oct 2021, ages 4–7); clearance expanded to ages 8–12 (Apr 2025). Pokemon content deal (Sep 2025) and first international license to ROHTO for Japan (Jun 2026).
HQ: Cambridge, MA, USA
Funding
$16M Series A (Jun 2023, USVP-led)
—